Jude E, Liow E, Shapiro J, Azad AA, Crumbaker M, Pranavan G, Hocking C, Roncolato F, Smith A, Wong S, Anton A, Johns J, Gibbs P, Tran B, Weickhardt A. Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia. Asia-Pacific Journal of Clinical Oncology. 2026;:10.1111/ajco.70164
Tyson MD, Nam J-K, Joshi SS, Uchio EM, Jung SI, Bivalacqua TJ, Steinberg GD, Shore ND, Burke JM, Kitamura H, Tran B, Li R. Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. The Lancet Oncology. 2026;27(8):10.1016/s1470-2045(26)00194-4
Hitchen N, Bedard PL, Winegarden N, Sweet J, Grubb A, Anson-Cartwright L, Chung P, Warde P, Moore M, Kwan EM, Tran B. NanoString profiling of DNA repair and apoptosis genes in testicular germ cell tumours with divergent chemotherapy outcomes.Therapeutic Advances in Medical Oncology. 2026;18:10.1177/17588359261475672
Tran B, Voskoboynik M, Kim S-W, Lemech C, Carcereny E, Rha SY, Ahn M-J, Felip E, Lee KH, Álvarez EC, Yang JC-H, Ascierto PA, Pulla MP, Kondo S, Kuboki Y, Freeman D, Song X, Blando J, Eck S, Song FJ, Tang Z, Kuziora M, Gainer SD, Mitchell P, Asare J, Ayyoub A, Achour I, Subramaniam DS, Im S-A. Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. Clinical Cancer Research. 2026;32(14):10.1158/1078-0432.ccr-25-3447
Tran B, Dorff T, Richey M, Hankinson E, Olsen P, Karwa S, Sharpe J, Braunlin M, Kim C. Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer. 2026;24(6):10.1016/j.clgc.2026.102609
To V, Thio N, Castle R, Macdonald S, Molden-Hauer T, Wells J, McMahon R, Bressel M, Tran B, Azad AA, Moon D, Appu S, Wong L-M, Murphy DG, Cuff K, Pryor D, Spain L, Au L, D’Souza C, Neeson PJ, Siva S. Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma. Nature Communications. 2026;17(1):10.1038/s41467-026-74255-x
Panasci J, Park CL, Tran B, Siu LL. Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours. British Journal of Cancer. 2026;135(1):10.1038/s41416-026-03450-w
Pan HYC, Homewood D, Lucas H, Dittmer B, Teh J, O’Brien JS, Liu J, Tran B, Chee J, Churchill JA, Lawrentschuk N, Corcoran NM. The Australian Penile Cancer Clinical Registry: a comprehensive national approach to data collection. BJU International. 2026;138(Suppl 2):10.1111/bju.70188
Sherry AD, To V, D’souza C, Kiany S, Thio N, Liu S, Sun X, Castle B, Macdonald S, Choi H, Seo A, Hara K, Pryor D, Azad A, Tran B, Au L, Spain L, Ludmir EB, Jonasch E, Tannir NM, Msaouel P, Neeson P, Haymaker C, Tang C, Siva S. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. European Urology. 2026;90(1):10.1016/j.eururo.2026.03.024
Xu YE, Hitchen N, Kamanat BV, O’Haire S, Harris W, Chan KH, Wilson M, Koyama T, Prasongsook N, Thambamroong T, Kho BP, Ting FIL, Vo TTP, Kim J, Voon P-J, Heong VYM, Ueno NT, Tran B, Tan DSW, Loong HHF. 177RO Regulatory approval delays for pembrolizumab and trastuzumab deruxtecan across the Asia-Pacific region. ESMO Open. 2026;11:10.1016/j.esmoop.2026.107978
